PURPOSE: Controversy exists as to whether the incidence of graft-versus-host disease
(GVHD) is increased after peripheral-blood stem-cell transplantation (PBSCT) when …

Cyclosporin remains the most widely used immunosuppressive agent in patients
undergoing allogeneic stem cell transplantation (SCT). The increased awareness of the …

Objective: The therapeutic options currently available for treating refractory graft‐vs.‐host
disease (GVHD) are limited. Therefore, the present study evaluated the efficacy of …

The combination of Cyclosporin A (CSA) and Methotrexate (MTX) is considered to be the
standard regimen for the prevention of graft-versus-host disease (GVHD) after stem cell …

The use of mycophenolate mofetil (MMF) for prophylaxis of aGVHD and/or for treatment of
acute or chronic GVHD is increasing. However, the benefit of MMF as an alternative to …

In order to determine optimal CsA trough blood concentrations (TBC) in the early post
transplantation period, we analysed relationships between TBC and acute graft-versus-host …

Cyclosporine is one of the most vital agents in the process of successful allogeneic
hematopoietic stem cell transplantation. Despite a long history and worldwide extent of …

The combination of CYA and short-course MTX is commonly used for GVHD prophylaxis
after allogeneic BMT. Severe mucositis and organ dysfunction early after transplantation …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The population pharmacokinetics
and limited sampling strategies for ciclosporin monitoring have been extensively studied in …

Autologous transplantation has an established role in the treatment of lymphoproliferative
disorders, but allogeneic transplantation remains controversial. In an attempt to reduce the …